WCN25-3960 OBSERVATIONAL ANALYSIS OF TREATMENT OUTCOMES AND ASSOCIATION OF PLA2R LEVELS IN PRIMARY MEMBRANOUS NEPHROPATHY IN A TERTIARY CARE CENTER OF EASTERN INDIA

Conclusions: In our study, Rituximab had almost similar outcomes compared to MPR in terms of remission (CR/PR) over a period of 6 months .But the relapse rate at the end of one year was significantly higher in Rituximab group .Despite this, it should be noted that Rituximab displayed a better adverse effect profile compared to MPR and is preferable in patients with multiple comorbidities and elderly age group.Further evaluation between these two treatment modalities of MN should involve a multicenter trial conducted with greater patient numbers and longer follow-up I have no potential conflict of interest to disclose.I did not use generative AI and AI-assisted technologies in the writing process.